A cervical cancer injection protects women for more than four years, so trials have shown.
Cervical cancer kills 1,000 plus women based in the UK each year; the vaccine protects women against the human papilloma virus, considered to be the main cause.
50% of young women based in the UK are considered to be infected with a high-risk strain of HPV by the age of 30.
The use of this drug is however controversial, as it is likely to be administered to girls as young as 10.
As HPV is transmitted through sex, certain critics have stated that treating girls so young with the vaccine may encourage under age sex.
The research has been published by The Lancet online. US researchers obtained smear test samples from 800 women who participated in the vaccine trial. The women got three doses of the vaccine or a placebo.
The researchers discovered that women who had had the vaccine had high levels of antibodies against the virus strains more than four years after receiving the last dose.
